Skip to main content
SpringerLink
Log in

Reply to Lixin Du et al

  • Correspondence
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

This article does not have any relevant original data.

References

  1. Du L LZ, Lan P, Huang H, Cheng W, Xia J (2022) Dose evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke? Eur J Clin Pharmacol

  2. Seo B, Su J, Song Y (2022) Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies. Eur J Clin Pharmacol 78(8):1205–1216

    Article  CAS  Google Scholar 

  3. Cherney DZ, Udell JA (2016) Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility. Circulation 134(24):1915–1917

    Article  Google Scholar 

  4. Ioannidis JP (2009) Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 181(8):488–493

    Article  Google Scholar 

  5. Fusar-Poli P, Radua J (2018) Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 21(3):95–100

    Article  Google Scholar 

Download references

Funding

There was no funding source for this study.

Author information

Authors and Affiliations

  1. Department of Epidemiology, Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, IN, 46202, USA

    Bojung Seo & Yiqing Song

  2. Cardiology Professional Services of Berkshire Medica Center, 777 North St, Pittsfield, MA, 01201, USA

    Jialin Su

Authors
  1. Bojung Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jialin Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yiqing Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Seo B wrote the main manuscript. Song Y substantively revised the manuscript. All authors reviewed and approved the manuscript.

Corresponding author

Correspondence to Yiqing Song.

Ethics declarations

Conflicts of Interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seo, B., Su, J. & Song, Y. Reply to Lixin Du et al. Eur J Clin Pharmacol 78, 1707–1708 (2022). https://doi.org/10.1007/s00228-022-03379-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-022-03379-y

Search

Navigation